Last updated: January 1, 2025
Introduction
BAY1817080, also known as eliapixant, is an investigational P2X3 receptor antagonist that was being developed by Bayer in collaboration with Evotec SE. Here, we will delve into the recent developments and the implications for the market.
Background of Eliapixant
Eliapixant was a promising drug candidate under evaluation for several potential indications, including endometriosis, refractory chronic cough, overactive bladder, and diabetic neuropathic pain. It was derived from a strategic alliance between Bayer and Evotec SE, a global drug discovery and development company[1][4].
Discontinuation of Phase II Development
In February 2022, Bayer announced the discontinuation of Phase II development for eliapixant. This decision was made following a thorough review of the available data, which indicated that the overall benefit of the drug no longer outweighed the risk in the actively pursued indications. This assessment led Bayer to conclude that further development was not justified[1][4].
Implications for Evotec SE
As a result of Bayer's decision, Evotec SE regained the rights to all P2X3 assets related to eliapixant. Evotec will evaluate the underlying data and consider all options for the future development of these assets. This decision does not impact Evotec's overall strategic goals as outlined in their Action Plan 2025[4].
Market Impact on Chronic Refractory Cough Treatment
The discontinuation of eliapixant is particularly significant in the context of the chronic refractory cough (CRC) treatment market. This market is projected to grow substantially, with an estimated valuation of USD 9.2 billion in 2023 and expected to reach USD 17.1 billion by 2033, growing at a CAGR of 6.39% during this period[2].
Current Market Landscape
The CRC market is driven by the growing prevalence of refractory chronic cough globally, increased healthcare spending, and heightened disease awareness. Other pipeline therapies, such as Gefapixant (Merck) and Orvepitant Maleate (Nerre Therapeutics), are in late and mid-stage developments and are expected to contribute to market growth[2].
Regional Market Dynamics
North America, particularly the USA, dominates the CRC market with a significant market share due to high disease burden and collaborative efforts among major pharmaceutical companies. The South Asia region is expected to witness the fastest growth, expanding at a CAGR of 6.2% over the forecast period[2].
Market Projections Without Eliapixant
Given the discontinuation of eliapixant, the market will rely on other pipeline therapies to drive growth. Here are some key projections:
- Global Market Value: The global CRC treatment market is expected to reach USD 17.1 billion by 2033, up from USD 9.2 billion in 2023, with a CAGR of 6.39%[2].
- Regional Growth: North America will continue to be a major market, while South Asia is expected to show the fastest growth rate during the forecast period[2].
- Competitive Landscape: Other drugs in development, such as Gefapixant and Orvepitant Maleate, will play a crucial role in meeting the unmet medical needs in the CRC market[2].
Expert Insights
Industry experts emphasize the importance of continuous innovation in drug development to address unmet medical needs. For example, the launch of new therapies and the advancement of pipeline candidates are critical for market expansion and patient care.
"The launch of pipeline therapies in late and mid-stage developments is anticipated to expand the growth quadrant of the Chronic Refractory Cough market size in the coming years."[2]
Statistics and Trends
- Market Size: The CRC market was valued at USD 9.2 billion in 2023 and is projected to reach USD 17.1 billion by 2033[2].
- Growth Rate: The market is expected to grow at a CAGR of 6.39% from 2023 to 2033[2].
- Regional Growth: South Asia is expected to grow at a CAGR of 6.2% during the forecast period[2].
Key Takeaways
- Discontinuation of Eliapixant: Bayer has discontinued the Phase II development of eliapixant due to a reassessment of the benefit-risk ratio.
- Market Impact: The discontinuation affects the CRC market, but other pipeline therapies are expected to drive market growth.
- Market Projections: The global CRC treatment market is projected to reach USD 17.1 billion by 2033, with North America and South Asia being key regions.
- Competitive Landscape: Other drugs in development will play a crucial role in meeting the unmet medical needs in the CRC market.
FAQs
What was eliapixant being developed for?
Eliapixant was being developed for several potential indications, including endometriosis, refractory chronic cough, overactive bladder, and diabetic neuropathic pain.
Why was the development of eliapixant discontinued?
The development of eliapixant was discontinued due to a review of available data that indicated the overall benefit no longer outweighed the risk in the actively pursued indications.
What impact does this have on Evotec SE?
Evotec SE has regained the rights to all P2X3 assets related to eliapixant and will evaluate the underlying data and consider all options for future development.
How does this affect the chronic refractory cough treatment market?
The discontinuation of eliapixant means that other pipeline therapies will drive the growth of the CRC market, which is projected to reach USD 17.1 billion by 2033.
What are the key regions driving the CRC market growth?
North America, particularly the USA, and South Asia are expected to be key regions driving the growth of the CRC market.
What is the projected growth rate of the CRC market?
The CRC market is expected to grow at a CAGR of 6.39% from 2023 to 2033.
Sources
- Bayer Press Release: "Bayer will discontinue phase II development candidate eliapixant (BAY 1817080)" - February 4, 2022.
- Future Market Insights: "Chronic Refractory Cough Treatment Market- Shares & Forecast" - October 2022.
- CBO Report: "CBO's Model of Drug Development: Ongoing Updates" - November 2024.
- Evotec SE Ad Hoc Release: "Evotec SE - Bayer discontinues clinical development candidate eliapixant (BAY1817080); Evotec regains the rights to all P2X3 assets" - February 2022.
- ResearchAndMarkets.com: "Chronic Refractory Cough Market - 2030" - March 2021.
